US pharmaceutical major Pfizer Inc. (NYSE: PFE) and Alliance Foundation Trials, LLC (AFT) have announced positive results from the Phase III PATINA trial for Ibrance (palbociclib), a CDK4/6 inhibitor. The trial data indicated that incorporating Ibrance into the standard-of-care first-line maintenance therapy—following induction chemotherapy—resulted in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), as assessed by investigators.
Ibrance Combination Therapy Outcomes
In the PATINA trial, patients who received Ibrance in combination with anti-HER2 therapy, which includes trastuzumab or trastuzumab plus pertuzumab, and endocrine therapy, achieved a median PFS of 44.3 months. This represents a noteworthy extension of more than 15 months compared to those treated with anti-HER2 therapy and endocrine therapy alone. While overall survival, a secondary endpoint of the trial, has not yet matured, the PFS results are a significant milestone in the treatment of HR+, HER2+ metastatic breast cancer.-Fineline Info & Tech
